Last reviewed · How we verify
Suvorexant 10 mg
At a glance
| Generic name | Suvorexant 10 mg |
|---|---|
| Also known as | Belsomra, belsomra 10mg |
| Sponsor | Walter Reed Army Institute of Research (WRAIR) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Orexin s Role in the Neurobiology of Substance Use Disorder (NA)
- A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) (PHASE3)
- Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors (PHASE4)
- The Effects of Orexin Antagonism on Fear Extinction in PTSD (PHASE4)
- Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study) (PHASE4)
- Suvorexant and Alcohol (EARLY_PHASE1)
- Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking (PHASE2)
- Suvorexant and Sleep/Delirium in ICU Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Suvorexant 10 mg CI brief — competitive landscape report
- Suvorexant 10 mg updates RSS · CI watch RSS
- Walter Reed Army Institute of Research (WRAIR) portfolio CI